Regeneron Sanofi COPD Trial Shows Mixed Results
Regeneron and Sanofi announced Phase 3 trial results for itepekimab, a potential COPD treatment for former smokers. AERIFY-1 met...
Regeneron and Sanofi announced Phase 3 trial results for itepekimab, a potential COPD treatment for former smokers. AERIFY-1 met...
The FDA granted Fast Track designation to Teva Pharmaceutical’s investigational anti-IL-15 antibody, TEV-53408, for celiac disease treatment. This designation...
Vaccinex announced new data on pepinemab’s mechanism of action in enhancing immune responses to checkpoint therapies in neoadjuvant head...
BioXcel Therapeutics announced positive safety results from the first 115 patients in its SERENITY At-Home Phase 3 trial of...
Spur Therapeutics announced preclinical data for FLT201, its gene therapy candidate for Gaucher disease, published in Molecular Therapy. The...
Vaxart dosed the first patient in the 10,000-participant phase of its Phase 2b clinical trial for its oral COVID-19...
Fate Therapeutics will present clinical and preclinical data from its off-the-shelf cell therapy platform at the European Congress of...
ORIC Pharmaceuticals announced positive preliminary data from a Phase 1b trial of ORIC-944, a potential best-in-class PRC2 inhibitor, combined...
Taysha Gene Therapies announced positive clinical data from Part A of its REVEAL trials for TSHA-102 in Rett syndrome,...
Intrommune Therapeutics’ Oral Mucosal Immunotherapy (OMIT) platform, delivered via a specialized toothpaste containing peanut protein (INT301), has shown promising...